VRCA · Verrica Pharmaceuticals Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date these consolidated financial statements are issued.”View the 10-Q filed Aug 6, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| $30.32M | $35.58M | $7.57M | $5.12M | $9.03M | $12M | — | — | — | — | |
| $2.6M | — | $2.6M | $500K | — | — | — | — | — | — | |
| $4.58M | — | $4.97M | $4.62M | — | — | — | — | — | — | |
| — | — | 65.64% | 90.24% | — | — | — | — | — | — | |
| $6.03M | $8.86M | $11.84M | $20.3M | $12.2M | $15.93M | $15.67M | $15.44M | $12.83M | $3.73M | |
| $17.37M | — | — | — | $17.41M | $26.98M | $24.51M | $14.64M | $9.05M | $727K | |
| $37.86M | $35.22M | $58.82M | $47.31M | $17.41M | — | — | — | — | — | |
| $58.7M | $47.76M | $73.49M | $70.88M | $30.33M | $42.91M | $40.18M | $30.08M | $21.88M | $4.46M | |
| -$28.38M | -$12.19M | -$65.92M | -$65.76M | -$21.3M | -$30.91M | -$40.18M | -$30.08M | -$21.88M | -$4.46M | |
| — | -34.25% | -871.25% | -1283.35% | -235.78% | -257.57% | — | — | — | — | |
| $3.73M | $7.74M | $9.41M | $3.96M | $2.17M | $4.3M | $3.03M | — | — | — | |
| $676K | $929K | $1.42M | $2.74M | $476K | $123K | $521K | $1.88M | $1.23M | — | |
| -$2.81M | -$5.7M | -$10.66M | -$1.24M | -$3.19M | -$4.17M | -$2.51M | $1.87M | $1.23M | -$2000 | |
| — | $0 | $0 | $0 | $0 | — | — | — | — | — | |
| -$31.18M | -$17.89M | -$76.58M | -$67M | -$24.49M | -$35.08M | -$42.69M | -$28.21M | -$20.65M | -$4.46M | |
| — | -50.27% | -1012.15% | -1307.47% | -271.11% | -292.33% | — | — | — | — | |
| — | — | — | — | — | — | — | — | -$20.65M | -$9.76M | |
| — | — | — | -$67M | -$24.46M | -$35.11M | -$42.71M | -$28.17M | -$20.67M | -$4.46M | |
| USD/shares | -$1.74 | -$1.68 | -$14.78 | -$14.80 | -$7.20 | -$13.00 | — | — | — | — |
| USD/shares | -$1.74 | -$1.68 | -$14.78 | -$14.80 | -$7.20 | -$13.00 | — | — | — | — |
| shares | — | 10.65M | 5.18M | 4.53M | 3.42M | 2.7M | 2.5M | 2.49M | 1.47M | 285.03K |
| shares | — | 10.65M | 5.18M | 4.53M | 3.42M | 2.7M | 2.5M | 2.49M | 1.47M | 285.03K |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 301 similar-size Biotechnology companies (of 536 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Segment | $35,577,000 | $7,566,000 | $5,124,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| License and Collaboration Revenue | $20,292,000 | $992,000 | — | — |
| Product | $15,285,000 | $6,574,000 | $4,658,000 | $0 |
| License And Collaboration Revenue Commercial Supply And Development | $2,300,000 | $1,000,000 | — | — |
| Collaboration | — | $992,000 | $466,000 | $9,032,000 |